According to a study released Tuesday by Brazil's Oswaldo Cruz Foundation (Fiocruz), patients who have taken the two-shot scheme of CoronaVac's drug would be better off if they receive a booster injection of the Pfizer vaccine.
Pharmaceutical giant Pfizer has announced it planned to submit a COVID-19 vaccine for children under the age of 5 to the Food and Drug Administration (FDA) of the United for emergency authorization. If approved, it would be the first such drug available in the United States for that age group.
Brazil's National Health Surveillance Agency (Anvisa) Friday released a statement warning of the differences between COVID-19 vaccines for children to highlight the specifics of newly-released drugs.
The European Medicines Agency (EMA) Thursday announced it had approved the use of Pfizer's anti-COVID-19 pill Paxlovid, which has thus become the first oral treatment cleared for use in the European Union. The new drug is a combination of the molecule PF-07321332 and the HIV antiviral Ritonavir.
Uruguay Tuesday became the fifth country to join the European Union's covid-19 certificate program. It is also South America's first.
Former members of Uruguay's Honorary Scientific Advisory Group (GACH) have recommended a third dose of vaccine against COVID-19 in addition to inoculating children aged 5 to 11.
Canada Wednesday began vaccinating children aged 5 to 11 against COVID-19 in the French-speaking Quebec, while Ontario officially launched its campaign Thursday.
The pharmaceutical company Pfizer Friday filed an application before Brazil's National Health Surveillance Agency (Anvisa) for its COVID-19 vaccine named Comirnaty to be cleared for use on patients aged 5 to 11 years old.
United States stocks closed the trading week at new records with NASDAQ hitting 16,000 points for the first time, following a strong jobs increase report from the US Labor Department.
The Food and Drug Administration (FDA) of the United States Friday issued an emergency clearance for the use of the Pfizer / BioNTech vaccine against COVID-19 on children aged 5 to 11, it was announced. The decision came three days after a recommendation from a scientific committee.